

Compassionate Use Program (CUP)

Approved by The Norwegian Medicinal Products Agency

Active substance	Indication	Date of approval	Responsible for the CUP
CUP available for patients			
Nimorazole tablets, 500 mg	Squamous cell Cancer of the Head and Neck (SCCHN)	2016-12-01	Inphena ApS Name: Søren Anker Nielsen Email: san@inphena.com Phone: (+45) 40 200 200
CUP no longer available for new patients			
Elranatamab (PF-06863135) 40mg/ml	Multiple Myeloma (MM)	2023-02-02 Ended: January 2024	Pfizer AS
Glofitamab (AG42296) 5 mg/ml solution for iv infusion	Relapsed / refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL), transformed Follicular Lymphoma (tFL) or Primary Mediastinal B-Cell Lymphoma (PMBCL)	2021-05-20	Roche Norge AS
Tebentafusp (IMCgp100) 0.2mg/mL solution for infusion	HLA-A*02:01 positive patients with unresectable or metastatic uveal melanoma	2022-01-16 Ended: May 2023	Immunocore, Ltd.
Mosunetuzumab (AG42295) 1 mg/1 mL, 10 mg/10 mL og 30 mg/30 mL	Relapsed / Refractory Follicular Lymphoma (R/R FL)	2021-10-14 Ended: 2022-10-21	Roche Norge AS
Pevenedistat (TAK-924/MLN4924) 10 mg/ml concentrate for solution for iv infusion	Higher risk myelodysplastic syndromes (HR-MDS), or low blast acute myelogenous leukemia (LB-AML)	2020-08-25	Takeda

Risdiplam (RO7034067) 60mg, mixture	Spinal muscular atrophy (SMA)	2020-05-08	Roche Norge AS
Zanamivir 10mg/ml Infusion bag.	Hospitalised patients severely ill with influenza infection	2011-02-25	GlaxoSmithKline Research & Development Limited, United Kingdom
Polatuzumabvedotin, 140mg concentrate for infusion	Relapsed or refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)	2019-02-01	Roche Norge AS
Entrectinib capsules, 100mg, 200mg	Solid Tumors harboring a NTRK Gene Fusion or Patients with Non-Small Cell Lung Cancer (NSCLC) harboring a ROS1 Gene Fusion (AG40852)	2019-03-07	Roche Norge AS
Quizartinib tablets, 20mg and 30mg	Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations	2019-03-12	Daiichi Sankyo Inc.
Lorlatinib tablets, 5mg, 25mg, and 100mg acetate solvate tablets or as 25mg or 50mg free base tablets	Advanced non-small cell lung cancer (NSCLC) with an ALK or ROS1 gene rearrangement	2018-09-05	Pfizer Norge AS
Brigatinib tablets, 90 mg and 180 mg	ALK positive Non-Small Cell Lung Cancer	2018-04-20	Takeda Pharmaceuticals AS,
Emicizumab, 150 mg/1 ml	Hemophilia A and FVIII Inhibitors	2017-11-01	Roche Norge AS
Ocrelizumab, 300 mg intravenous infusion	Primary Progressive Multiple Sclerosis (PPMS)	2017-06-07	Roche Norge AS

Pembrolizumab, intravenous infusjon 2 mg/kg	Metastatic Melanoma	2014-09-09	MSD Norge AS
Ibrutinib capsules, 140mg	Relapsed or Refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma with Deletion 17p	2014-05-06	Janssen-Cilag AB
Cobimetinib (GDC-0973) 20 mg	advanced/metastatic BRAF ^{V600} mutation-positive melanoma	2015-06-25	Roche Norge AS
Combination regimen of trametinib and dabrafenib. Dabrafenib 150 mg Trametinib 2 mg	BRAF activating mutation-positive metastatic melanoma	2015-08-22	GlaxoSmithKline (GSK) AS, Oslo
Daclatasvir, 60 mg	Chronic hepatitis C	2014-06-23	Bristol-Mayers Squibb AS
Boceprevir	Hepatitis C	2011-05-05	MSD
Abiratrone	Metastatic Advanced Prostate Cancer	2011-11-19	Jansen Cilag
Crizotinib (PF-02341066)	Cancer (Positive ALK-fusion)	2011-10-13	Pfizer
Aflibercept	Metastatic Colorectal Cancer (mCRC)	2011-09-28	Sanofi